Palo Alto Health Sciences, Inc. (PAHS) recently announced it has obtained U.S. Food and Drug Administration (FDA) clearance for Freespira. Freespira is PAHS’s flagship digital therapeutic, and intended for the treatment of post-traumatic stress disorder (PTSD).
Studies of Freespira have shown that most people experience a significant reduction—or complete elimination—of panic attacks after completing treatments of it. This is significant, as 7-8% of Americans are estimated to receive a diagnosis of PTSD each year. Recent studies have demonstrated satisfaction rates of 90% in individuals using Freespira after six months of post-treatment. PAHS cites one of Freespira’s strengths as being the fact that it allows individuals to avoid the adverse effects that can result from the usage of exposure-based treatments.
Palo Alto Health Sciences, Inc. is a privately held digital therapeutic company revolutionizing behavioral health care with evidence-based, non-invasive, drug-free solutions to treat mental health conditions. Their first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks, and other symptoms of panic.
Contact Information: Palo Alto Health Sciences, 12020 113th Avenue Northeast, Suite 215, Kirkland, Washington 98034; Website: www.freespira.com